Compare Adaptive Biotechnologies Corp (ADPT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Illumina, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Illumina, Inc. trades at $186.52 (market cap $29.01B). The key difference: Illumina, Inc. is far larger — about 8.7× Adaptive Biotechnologies Corp's market cap, and Illumina, Inc. is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | ILMN | |
|---|---|---|
Market Cap | $3.33B | $29.01B |
Sector | Health | Health |
52-Week High | $22.37 | $194.33 |
52-Week Low | $10.24 | $91.00 |
Enterprise Value | $3.19B | $30.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ILMN trades at $191.76, up 1.63% with bullish technical momentum and strong earnings beats. The stock shows robust profitability with 66.2% gross margins and 19.42% net income margins, though valuations remain elevated with a P/E of 34.31. Recent product launches like StrataMap Spatial and NovaSeq X demand drive growth, while Roche's new Axelios sequencer introduces competitive pressure. Cash flow improved to $291M in 2025 after prior volatility.
Outlook remains positive with analyst consensus at Buy (51%) and a $168.89 price target, though current price exceeds consensus. Key risks include rising debt-to-asset ratios (29.93% in 2025) and China market challenges. Upside depends on execution against new competition and sustaining high-margin sequencing growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
